Skip to main content
Fig. 5 | Cardiovascular Diabetology

Fig. 5

From: Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double‐blind placebo‐controlled clinical trials

Fig. 5

Changes in FGF21 levels. Baseline levels indicate mean ± SD, and bars indicate LS mean change (95 % CI) from baseline to Week 12 (LOCF). *** p < 0.001 vs. placebo (ANCOVA with baseline value as covariate). FGF21 fibroblast growth factor 21, SD standard deviation, LS least squares, CI confidence interval, LOCF last observation carried forward, ANCOVA analysis of covariance

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840